Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced ...
Findings from preclinical studies could point to therapeutic strategies for Huntington’s disease, as well as other neurodegenerative disorders and potentially cancer.
The TV personality, 48, was admitted to hospital back in April 2023 after suffering horrific headaches and blackouts, but had ...
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts ...
Each indicator can be subtle and easy to miss—and one may even be praised as a good health outcome at first.
Dyne Therapeutics is advancing z-rostudirsen toward approval for DMD after data showed increased dystrophin and early functional trends.
Mitochondria are central regulators of cellular metabolism, redox balance, and cell survival in the nervous system. In recent years, growing evidence has ...
In A Nutshell Researchers in Japan built an AI system that constructs a personalized virtual brain from each individual’s brain connectivity scan, creating a unique digital twin for every person. In ...